September 22, 2014 2:39 PM ET

Biotechnology

Company Overview of Targazyme, Inc.

Company Overview

Targazyme, Inc., a biotechnology company, develops and commercializes products in the fields of cell and immunotherapy. The company’s products include TZ101 that attaches the sugar fructose to therapeutic cells, such as stem cells or immune cells to increase the ability of those cells to attach to selectins, which are proteins that are up regulated under conditions of inflammation, ischemia, and tissue damage. Its TZ101 is used for various applications for patients with cancer, such as cord blood transplantation for hematological malignancies, regulatory T cells and mesenchymal stem cells for graft versus host diseases, and natural killer cells for multiple myeloma and leukemia; Ischemic dis...

3200 County Road 104

Floresville, TX 78114

United States

Founded in 2005

Phone:

210-560-7689

Key Executives for Targazyme, Inc.

Co-Founder
Co-Founder and Vice President of Manufacturing
Age: 58
Co-Founder and Vice President of Research
Associate Chief Medical Officer
Senior Vice President of Regulatory Affairs & Quality Assurance
Age: 71
Compensation as of Fiscal Year 2014.

Targazyme, Inc. Key Developments

TargaZyme, Inc. Appoints Christopher Calhoun to Business Advisory Board

TargaZyme, Inc. announced that it has appointed Christopher Calhoun to its Business Advisory Board. Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer.

Targazyme, Inc. Appoints Mark W. Schwartz to Board of Directors

Targazyme, Inc. (formerly America Stem Cell, Inc.) announced that it has appointed Mark W. Schwartz, Ph.D. to the company's Board of Directors. Dr. Schwartz will serve the company as an independent member of the Board. As an independent director, Dr. Schwartz will assist in the company in further enhancing its corporate governance protocols and oversight committees, as well as assist management in setting and meeting corporate goals, including establishing key strategic partnerships and providing guidance on long-term capital raising in both private and public markets. With the appointment of Dr. Schwartz as the company's fourth Board member and third independent director, the company has achieved Sarbanes-Oxley compliance with respect to Board composition.

Targazyme, Inc. Presents at 16th Annual BIO CEO & Investor Conference 2014, Feb-10-2014 11:30 AM

Targazyme, Inc. Presents at 16th Annual BIO CEO & Investor Conference 2014, Feb-10-2014 11:30 AM. Venue: The Waldorf-Astoria Hotel, Conrad Room, New York, New York, United States.

Similar Private Companies By Industry

Company Name Region
CDG Therapeutics, Inc. United States
CoDa Therapeutics, Inc. United States
Pregentis Inc. United States
Asahi Kasei Technikrom, Inc United States
Anesta Corp. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Targazyme, Inc., please visit targazyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.